Independent Antibodies: Western Blot: NG2/MCSP Antibody [NBP1-21361] - NG2 Antibody [NBP1-21361] - Whole cell lysate from HeLa cells. MCSP was also immunoprecipitated by rabbit anti-MCSP antibody NBP1-21362.
Immunocytochemistry/ Immunofluorescence: NG2/MCSP Antibody [NBP1-21361] - NG2 Antibody [NBP1-21361] - Primary cultured trabecular meshwork cells from porcine eye. Left non stretched TM cells; Right 24 hours stretched TM ...read more
The immunogen recognized by this antibody maps to a region between residue 575 and 625 of human melanoma-associated chondroitin sulfate proteoglycan (chondroitin sulfate proteoglycan 4 ) using the numbering given in entry NP_001888.2 (GeneID 1464).
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Melanoma chondroitin sulfate proteoglycan (MCSP) is a cell-surface antigen expressed early in melanoma progression. It has been found to be involved in the spreading, invasion, and migration of human melanoma. MCSP influences melanoma behavior via the activation of the Cdc42 GTPase and phosphorylation of p130Cas. MCSP also activates signaling cascades involving FAK and ERK1/ERK2. In addition to its expression in melanoma cells, MCSP is also found in breast carcinomas, gliomas, neuroblastomas, and acute leukemias. MCSP is being considered as a target antigen for cancer immunotherapy.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.